Metformin has previously been shown to decrease circulating levels of CRP, IL-6, and TNF-α in patients with type 2 diabetes [81], however this finding was not replicated in our subjects who were nondiabetic and nonprediabetic. Here, IL6 is linked to type 2 diabetes mellitus.